$3.000
-0.399 (-13.29%)At close
SXTC News
SXTC Events
China SXT Pharmaceuticals Issues 4.5M Units at $2.00 Each
China SXT Pharmaceuticals announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4.5M units, consisting of one Class A ordinary share of the company and one common warrant at a purchase price of $2.00 per Unit in a registered direct offering. Each of the Warrants will have an exercise price of $3.20 per Class A Class A ordinary share, will be immediately exercisable upon issuance, and will expire on the one year anniversary of the issuance date. The aggregate gross proceeds to the company of this offering are expected to be approximately $9M, before deducting placement agent fees and other offering expenses payable by the company. The transaction is expected to close on or about July 24, subject to the satisfaction of customary closing conditions. Univest Securities is acting as the sole placement agent.
Company Not Selling 157.5M Class A Ordinary Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 157.5M Class A ordinary shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
China SXT Pharmaceuticals Launches AI Initiative to Enhance TCM Supply Chain
China SXT Pharmaceuticals announced as part of its Artificial Intelligence Insight Initiative to explore the application of Artificial Intelligence and related digital technologies across the Traditional Chinese Medicine, TCM, raw-material supply chain. This initiative is part of the Company's long-term plan to improve supply chain transparency, operational stability, and quality oversight. "Applying AI to our supply chain management is an important part of our long-term operational planning," said Feng Zhou, Co-Chief Executive Officer and Director of China SXT. "Through the use of digital tools and AI-supported analysis, we aim to enhance supply chain reliability and strengthen our quality assurance capabilities."
China SXT Pharmaceuticals Enters Agreement to Sell 66.67M Shares
China SXT Pharmaceuticals announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66.67M Class A ordinary shares of the company at a purchase price of 15c per share in a registered direct offering. The aggregate gross proceeds to the company of this offering are expected to be approximately $10M. The transaction is expected to close on or about January 12, subject to the satisfaction of customary closing conditions. Univest Securities is acting as the sole placement agent.
Major Averages Mixed as Oil Prices Surge Nearly 4%
The major averages had a mixed day as profit-taking and risk aversion appeared to take hold ahead of the forthcoming jobs report. After major indexes hit record highs in recent sessions, broader sentiment reflects a shift to a more measured and selective market, with investors digesting geopolitical developments, mixed earnings cues and fresh macro indicators.Looking to commodities, gold was mostly unchanged, while oil was sharply higher, climbing nearly 4%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Shares of defense companies surged after President Trump said on social media yesterday that he wants theto be $1.5T, not $1TJPMorgan Chasewillof the Apple Card, taking over from Goldman SachsApplied DigitalreportedParamount Skydancereaffirmed itsfor Warner Bros. DiscoveryGlencorewith Rio Tintoabout a possible combination2. WALL STREET CALLS:Alphabetto Overweight at Cantor FitzgeraldNeedhamNikeon its slower than expected turnaround while Deutsche Bank resumed coverage with a Hold ratingPiper Sandlerthe "Big 3" U.S. automakers General Motors (GM), Fordand Stellantisto OverweightUBSGapto Buy ahead of an expected positive earnings inflectionAlcoato Underweight at JPMorgan3. AROUND THE WEB:After AbbVie (ABBV) denied it is in talks to acquire Revolution Medicines, FT reported that Merckis in talks to buy the cancer drug makerNvidiarequires full upfront payment from Chinese customers looking to buy H200 AI chips, Reuters reportsFordintends to introduce eyes-off technology on an upcoming $30,000 all-electric car in 2028, CNBC saysChina on Wednesday unveiled rules banning major platforms like Alibabaand JD.comfrom coercing merchants into discounts or practices seen as disrupting market order, Bloomberg reportsChevronis in discussions with the U.S government to expand a key license to operate in Venezuela so it can increase crude exports to its own refineries and sell to other buyers, Reuters says4. MOVERS:flyExclusiveincreases after signing anwith StarlinkEnlivengains after reporting "positive" initialfor ELVN-001 in CMLChina SXT Pharmaceuticalshigher in New York after announcing the launch ofImmuneeringlower after reporting survival and safety data from itsCorMedixfalls afterfor Q4 and FY265. EARNINGS/GUIDANCEConstellation Brandsreportedand reiterated its FY26 EPS guidanceCommercial Metalsand provided guidance for Q2, with CEO Peter Matt commenting, "The first quarter market an exceptional start to 2026"RPM, with EPS and revenue missing consensusHelen of Troyand cut its guidance for FY26Simply Foodsand provided guidance for FY26, with CEO Geoff Tanner commenting, "Our first quarter financial performance came in modestly ahead of our expectations"INDEXESThe Dow rose 270.03, or 0.55%, to 49,266.11, the Nasdaq lost 104.26, or 0.44%, to 23,480.02, and the S&P 500 advanced 0.53, or 0.0077%, to 6,921.46.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.